Intellia Therapeutics Inc (NASDAQ:NTLA) was up 2.9% during trading on Monday . The stock traded as high as $23.47 and last traded at $22.94, with a volume of 162,752 shares. The stock had previously closed at $22.30.

Several equities research analysts have recently commented on NTLA shares. Jefferies Group restated a “buy” rating and set a $33.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, August 17th. Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Intellia Therapeutics in a research note on Tuesday. Leerink Swann upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a research note on Friday, August 5th. Finally, Credit Suisse Group AG started coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $35.50.

The firm has a 50-day moving average price of $19.32 and a 200 day moving average price of $23.08. The firm’s market cap is $824.99 million.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.